MedTrace Logo

Interactive Voice Response Telephone Technology for the Treatment of Smoking in Patients With Heart Disease

NCT00449852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 442

Last updated 2011-04-29

No results posted yet for this study

Summary

A randomized control trial is planned to evaluate an interactive voice response (IVR) mediated follow-up and triage system, against usual care, to help smokers hospitalized with Coronary Heart Disease (CHD) to quit smoking. The investigators hypothesize that compared to usual care, participants in the IVR group will; a) have a significantly higher 7-day point prevalence abstinence rate at 26 and 52 weeks after hospital discharge, b) will have a higher rate of continuous abstinence at 26 and 52 weeks after hospital discharge, c) will use a greater number of proven effective interventions over time, and d) will develop greater self-efficacy with respect to smoking cessation, over time.

Conditions

Interventions

BEHAVIORAL

Interactive Voice Response

The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.

Sponsors & Collaborators

  • Heart and Stroke Foundation of Ontario

    collaborator OTHER

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Robert D Reid, PhD. · University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre

  • Andrew Pipe, C.M, MD · University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre

  • Bonnie Quinlan, BSCN · University of Ottawa Heart Institute, Prevention and Rehabilitation Centre

  • Heather Sherrard, BSCN, MHA · Ottawa Heart Institute Research Corporation

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449852 on ClinicalTrials.gov